Vnitr Lek 2018, 64(2):169-172 | DOI: 10.36290/vnl.2018.025

Diffuse alveolar hemorrhage - acute, life-threatening situation in rheumatology

Petr Bradna1,*, Jan Maňák2, Tomáš Soukup1, Michal Kodeda1, Marcela Drahošová3, Jan Tomš1
1 II. interní gastroenterologická klinika LF UK a FN Hradec Králové
2 III. interní gerontometabolická klinika LF UK a FN Hradec Králové
3 Ústav klinické imunologie a alergologie LF UK a FN Hradec Králové

Diffuse alveolar hemorrhage (DAH) is a life-threatening acute manifestation of systemic diseases, the most commonly of systemic vasculitis. Clinically DAH manifests by a rapidly progressive respiratory and renal failure. The decisive for diagnose is immediate bronchoscopic examination with the bronchoalveolar lavage examination. CT mostly show bilateral pulmonary infiltrates, in blood picture rapidly come to anemia. In the majority of patients it can be found positive ANCA antibodies. DAH should be suspected in the case of acute respiratory failure also in patients without history of systemic disease. On the set of 33 patients with acute DAH episode, we demonstrate the importance of rapid diagnosis and aggressive therapy. In a third of our patients was DAH the first manifestation of systemic disease. Immunomodulatory treatment must be initiated immediately after diagnose. Hospital mortality in our group was 27 %, although 42 % of the patients were required ventilation support and one-third of patients had acute renal failure. After handling of acute episode of DAH is the prognosis quoad vitam promising.

Keywords: bronchoalveolar fluid; diffuse alveolar haemorrhage; granulomatosis with polyangiitis; intensive care in rheumatology; vasculitis

Received: September 27, 2017; Accepted: November 19, 2017; Published: February 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bradna P, Maňák J, Soukup T, Kodeda M, Drahošová M, Tomš J. Diffuse alveolar hemorrhage - acute, life-threatening situation in rheumatology. Vnitr Lek. 2018;64(2):169-172. doi: 10.36290/vnl.2018.025.
Download citation

References

  1. Park MS. Diffuse Alveolar Hemorrhage. Tuberc Respir Dis 2013; 74(4): 151-162. Dostupné z DOI: <http://dx.doi.org/10.4046/trd.2013.74.4.151>. Go to original source... Go to PubMed...
  2. Martínez-Martínez MU, Herrera-van Oostdam DA, Abud-Mendoza C. Diffuse alveolar hemorrhage in autoimmune diseases. Curr Rheumatol Rep 2017; 19(5): 27. Dostupné z DOI: <http://dx.doi.org/10.1007/s11926-017-0651-y>. Go to original source... Go to PubMed...
  3. Quadrelli S, Dubinsky D, Solis M et al. Immune diffuse alveolar hemorrhage: Clinical presentation and outcome. Respir Med 2017; 129: 59-62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rmed.2017.06.003>. Go to original source... Go to PubMed...
  4. Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2016; 68(6): 1467-1476. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39562>. Erratum in Financial Disclosure Information on One Author in the Article by Cartin-Ceba et al (Arthritis Rheumatol, June 2016). [Arthritis Rheumatol 2016]. Go to original source... Go to PubMed...
  5. Hassan TM, Hassan AS, Igoe A et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow-up in ANCA-associated vasculitis. BMC Immunology 2014; 15: 20. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2172-15-20>. Go to original source... Go to PubMed...
  6. Aceves EP, Cristóbal MP, Espinola Reyna GA et al. Chronic respiratory dysfunction due to diffuse alveolar hemorrhage in patients with systemic lupus erythematosus and primary vasculitis. Reumatol Clin 2013; 9(5): 263-268. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reuma.2013.01.008>. Go to original source... Go to PubMed...
  7. Kim D, Choi J, Cho SK et al. Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2017; 46(6): 782-787. Dostupné z DOI: <http://dx.doi.org/10.1016/j.semarthrit.2016.09.004>. Go to original source... Go to PubMed...
  8. Hughes KT, Beasley MB. Pulmonary manifestations of acute lung injury. More Than Just Diffuse Alveolar Damage. Arch Pathol Lab Med 2017; 141(7): 916-922. Dostupné z DOI: <http://dx.doi.org/10.5858/arpa.2016-0342-RA>. Go to original source... Go to PubMed...
  9. Thompson G, Klecka M, Roden AC et al. Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. Respirology 2016; 21(4): 734-738. Dostupné z DOI: <http://dx.doi.org/10.1111/resp.12738>. Go to original source... Go to PubMed...
  10. Kostianovsky A, Hauser T, Pagnoux C et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012; 30(Suppl 70): S77-S82. Go to PubMed...
  11. de Prost N, Parrot A, Cuquemelle E et al. Immune diffuse alveolar hemorrhage: a retrospective assessment of a diagnostic scale. Lung 2013; 191(5): 559-563. Dostupné z DOI: <http://dx.doi.org/10.1007/s00408-013-9491-3>. Go to original source... Go to PubMed...
  12. Rawal G, Kumar R, Yadav S. ECMO rescue therapy in diffuse alveolar haemorrhage: A case report with review of literature. J Clin Diagn Res 2016; 10(6): OD10-OD11. Dostupné z DOI: <http://dx.doi.org/10.7860/JCDR/2016/20649.7969>. Go to original source... Go to PubMed...
  13. Baker MS, Diab KJ, Carlos WG et al. Intrapulmonary recombinant factor VII as an effective treatment for diffuse alveolar hemorrhage: A case series. J Bronchology Interv Pulmonol 2016; 23(3): 255-258. Dostupné z DOI: <http://dx.doi.org/10.1097/LBR.0000000000000286>. Go to original source... Go to PubMed...
  14. Frausová D, Hrušková Z, Lánská V et al. Long-term outcome of patients with ANCA associated vasculitis treated with plasma exchange: a retrospective, single-centre study. Arthritis Res Ther 2016; 18: 168. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075-016-1055-5>. Go to original source... Go to PubMed...
  15. Yates M, Watts RA, Bajema IM et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75(9): 1583-1594. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016-209133>. Go to original source... Go to PubMed...
  16. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68(3): 310-317. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2008.088096>. Go to original source... Go to PubMed...
  17. Roccatello D, Sciascia S, Rossi D et al. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. Oncotarget 2017; 8(32): 52072-52077. Dostupné z DOI: <http://dx.doi.org/10.18632/oncotarget.18120>. Go to original source... Go to PubMed...
  18. Tashiro H, Takahashi K, Sadamatsu H et al. Chronic and asymptomatic diffuse alveolar haemorrhage with microscopic polyangiitis: A case report and review of the literature. Case Rep Rheumatol 2016; 2016: 1658126. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/1658126>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.